Erasca Announces Proposed Public Offering of $150 Million of Common Stock
Rhea-AI Summary
Erasca (Nasdaq: ERAS) announced a proposed underwritten public offering of $150.0 million of common stock with a 30-day underwriter option to purchase up to an additional $22.5 million of shares. The company said it will use net proceeds together with existing cash and marketable securities to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes. The offering will be made under a shelf registration statement declared effective on August 22, 2025, and a preliminary prospectus supplement will be filed with the SEC. There is no assurance the offering will be completed or as to final size or terms.
Positive
- $150.0M proposed capital to fund R&D
- Underwriters named: J.P. Morgan, Morgan Stanley, Jefferies, Evercore ISI
- Shelf registration effective Aug 22, 2025 enables offering flexibility
Negative
- Potential shareholder dilution from issuance of $150.0M equity
- No assurance the proposed offering will be completed or on stated terms
- Underwriters have 30-day option to add $22.5M more shares
News Market Reaction – ERAS
In the Jan 21 session, ERAS gained 2.45%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.9% during that session. Argus tracked a trough of -14.6% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Clinical data update | Positive | -7.8% | Early Phase 1 RAS data with multiple partial responses and good safety. |
| Jan 06 | Conference presentation | Positive | +4.0% | Announcement of J.P. Morgan Healthcare Conference presentation and webcast. |
| Nov 25 | Conference participation | Positive | +6.2% | Evercore Healthcare Conference appearance with webcast and investor meetings. |
| Nov 12 | Earnings and pipeline | Positive | +12.3% | Q3 2025 financials, strong cash position, and 2026 clinical milestones. |
| Nov 06 | Patent issuance | Positive | +1.8% | New U.S. patent covering ERAS-0015 composition of matter through 2043. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been followed by positive price reactions, with one notable selloff after encouraging clinical data.
Over the last few months, Erasca has highlighted patent protection, financial strength, and clinical progress. On Nov 12, 2025, Q3 results showed $362.4M in cash and funding into H2 2028, which coincided with a 12.29% gain. Conference participation in Nov 2025 and Jan 2026 also aligned with positive moves. However, promising Phase 1 RAS data on Jan 12, 2026 saw a 7.84% decline, showing that strong clinical headlines have not always produced supportive price action.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
base prospectus regulatory
preliminary prospectus supplement regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions,
Erasca intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.
J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the proposed offering.
The securities described above are being offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) and was declared effective on August 22, 2025. A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement for this offering may be obtained, when available, by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Forward Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the completion, timing and size of the proposed offering and our intended use of proceeds therefrom, and the grant of the option to purchase additional shares. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
